GlassScriptPhysician profile
Alberto E Garcia
NPI 1518047547
$3,069.53
in general payments reported to CMS, 2019-2025
25 companies · $73.74 in 2025
The $73.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $330 · 2021: $650 · 2022: $722 · 2023: $386 · 2024: $598 · 2025: $73.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $642.02 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $431.94 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $393.51 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $296.38 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $225.91 | 2021-2024 | Spravato |
| Amgen INC. | $125.76 | 2023-2024 | Repatha, Otezla |
| Abbvie INC. | $114.40 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.60 | 2022 | |
| Pfizer INC. | $94.43 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $78.73 | 2019-2021 | |
| Mannkind Corporation | $73.34 | 2020-2021 | |
| Biogen, INC. | $73.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.44 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.20 | 2019 | |
| Genentech USA, INC. | $55.20 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.42 | 2020-2024 | Xifaxan |
| Exact Sciences Corporation | $34.23 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $28.83 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $20.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.66 | 2021 | |
| Lundbeck LLC | $15.65 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $15.12 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $12.95 | 2019 | |
| Dexcom, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.